Table 1. Thalidomide-based induction... | American Society of Hematology

Table 1.

Thalidomide-based induction regimens prior to ASCT: results of comparative studies.

Author	Rajkumar¹²	Cavo¹³	Macro¹⁴	Lokhorst¹⁵	Morgan¹⁶
* Low Molecular Weight Heparin prophylaxis
Abbreviations: NA, not available; DVT, deep vein thrombosis; TD, thalidomide/dexamethasone; D, dexamethasone; VAD, vincristine/adriamycin/dexamethasone; TCD, thalidomide/cyclophosphamide/dexamethasone; CVAD, cyclophosphamide/vincristine/adriamycin/dexamethasone; CR, complete response; VGPR, very good partial response; PR, partial response
Treatment	TD vs D	TD vs VAD	TD vs VAD	TD vs VAD	TCD vs CVAD
	4 cycles	4 months	4 months	3 cycles	NA
Number of patients	201	200	204	402	251
Results prior to ASCT, %
CR	4 vs 0	10 vs 8	12.5	4 vs 2	20 vs 12
> VGPR	—	19 vs 14	35 vs 17	33 vs 15	38 vs 26
> PR	69 vs 52	76 vs 52	—	72 vs 54	96 vs 83
Results after ASCT, %
CR	—	—	—	16 vs 11	58 vs 41
> VGPR	—	—	44 vs 42	49 vs 32	67 vs 43
> PR	—	—	—	79 vs 76	99 vs 96
DVT	17 vs 3	15 vs 2	23 vs 7.5	8 vs 4*	NA

Author	Rajkumar¹²	Cavo¹³	Macro¹⁴	Lokhorst¹⁵	Morgan¹⁶
* Low Molecular Weight Heparin prophylaxis
Abbreviations: NA, not available; DVT, deep vein thrombosis; TD, thalidomide/dexamethasone; D, dexamethasone; VAD, vincristine/adriamycin/dexamethasone; TCD, thalidomide/cyclophosphamide/dexamethasone; CVAD, cyclophosphamide/vincristine/adriamycin/dexamethasone; CR, complete response; VGPR, very good partial response; PR, partial response
Treatment	TD vs D	TD vs VAD	TD vs VAD	TD vs VAD	TCD vs CVAD
	4 cycles	4 months	4 months	3 cycles	NA
Number of patients	201	200	204	402	251
Results prior to ASCT, %
CR	4 vs 0	10 vs 8	12.5	4 vs 2	20 vs 12
> VGPR	—	19 vs 14	35 vs 17	33 vs 15	38 vs 26
> PR	69 vs 52	76 vs 52	—	72 vs 54	96 vs 83
Results after ASCT, %
CR	—	—	—	16 vs 11	58 vs 41
> VGPR	—	—	44 vs 42	49 vs 32	67 vs 43
> PR	—	—	—	79 vs 76	99 vs 96
DVT	17 vs 3	15 vs 2	23 vs 7.5	8 vs 4*	NA